The metabolic bone disease is a well-known complication in newborn children fed with long-term parenteral nutrition. The principal cause is a failure to supply a sufficient quantity of calcium and phosphorus when inorganic phosphorus salts are used. This failure is due to the solubility of these salts in aqueous solutions. It has been shown that organic phosphorus compounds are more compatible with calcium in parenteral nutrition solutions. The aim of this study is to evaluate the efficacy and tolerance of sodium glycerophosphate in comparison with potassium phosphate in newborns who require parenteral nutrition. A randomized double-blind clinical study was planned. The patients were divided into two groups: one was treated with glycerophosphate, the other with potassium phosphate. Calcium and phosphorus plasma concentrations through time were taken as primary efficacy variable, while the accumulated urinary excretion of calcium and phosphorus constituted the secondary efficacy variable. For safety evaluation, the clinical and laboratory parameters specified in the protocol were controlled, and any adverse event was protocolled. Forty three newborns were included. After analysing the data obtained during the study of the area under the curve, we obtained a p >0.05 both for phosphorus and calcium in plasma. The same result was reached after analysing the secondary efficacy variable. The clinical characteristics and safety variables showed a similar pattern in both groups. We may conclude that sodium glycerophosphate is a product of equal efficacy and safety as potassium phosphate for supplementation of phosphorus in parenteral nutrition solutions.
|Journal||Revista Espanola de Pediatria|
|Publication status||Published - 1 Nov 2013|
- Parenteral Nutrition
- Sodium Glycerophosphate